Raymond James Financial Services Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-551
Closed -$21K 3195
2020
Q4
$21K Sell
551
-8,581
-94% -$321K ﹤0.01% 2946
2020
Q3
$493K Buy
9,132
+79
+0.9% +$14.3K ﹤0.01% 1973
2020
Q2
$2.28M Sell
9,053
-2,163
-19% -$437K 0.01% 1057
2020
Q1
$1.76M Buy
11,216
+1,071
+11% +$181K 0.01% 947
2019
Q4
$1.66M Sell
10,145
-149
-1% -$22K 0.01% 1256
2019
Q3
$1.5M Buy
10,294
+170
+2% +$29.6K 0.01% 1249
2019
Q2
$2.1M Sell
10,124
-32
-0.3% -$6.85K 0.01% 1082
2019
Q1
$2.12M Sell
10,156
-1,629
-14% -$359K 0.01% 1033
2018
Q4
$2.06M Sell
11,785
-1,663
-12% -$332K 0.01% 883
2018
Q3
$3.05M Sell
13,448
-820
-6% -$133K 0.01% 855
2018
Q2
$2.16M Buy
14,268
+119
+0.8% +$21.6K 0.01% 975
2018
Q1
$2.59M Sell
14,149
-352
-2% -$79.1K 0.01% 821
2017
Q4
$3.09M Sell
14,501
-316
-2% -$67.6K 0.02% 726
2017
Q3
$3.18M Buy
14,817
+608
+4% +$119K 0.02% 714
2017
Q2
$2.69M Buy
14,209
+746
+6% +$146K 0.02% 751
2017
Q1
$3.33M Buy
13,463
+704
+6% +$173K 0.03% 616
2016
Q4
$3.23M Buy
12,759
+767
+6% +$176K 0.03% 583
2016
Q3
$2.44M Buy
11,992
+3,167
+36% +$394K 0.02% 676
2016
Q2
$792K Sell
8,825
-336
-4% -$26.3K 0.01% 1162
2016
Q1
$497K Buy
9,161
+4,472
+95% +$197K 0.01% 1256
2015
Q4
$232K Buy
+4,689
New +$239K ﹤0.01% 1495

Other funds holding CRBP

Raymond James Financial Services Advisors's CRBP Position: Q1 2021 in Review

Raymond James Financial Services Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q1 2021, closing a stake of 551 shares — an estimated $21K sold.

Raymond James Financial Services Advisors first reported a position in CRBP in Q4 2015 and held it in 21 quarters. The position peaked at $3.33M in Q1 2017. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2021.

  • Raymond James Financial Services Advisors reported no remaining Corbus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 551 Corbus Pharmaceuticals shares in Q1 2021, an estimated $21K.
  • Raymond James Financial Services Advisors first reported a position in Corbus Pharmaceuticals in Q4 2015 and held it in 21 quarters.
  • Raymond James Financial Services Advisors's Corbus Pharmaceuticals position peaked at $3.33M in Q1 2017.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2021, filed 14 May 2021.